Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This is a phase IIIb comparative study of entecavir 1.0 mg once daily (QD) vs. adefovir 10 mg
QD in patients who have chronic hepatitis B infection and hepatic decompensation. The
patients are treated for 96 weeks after the last subject is randomized.